01
Mar
Blog
27
Feb
ELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 The U.S. oral migraine drug market...
18
Feb
SAN DIEGO, February 18, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq:SRNE, “Sorrento”) today posted an IRS Form 8937 (the “Form 8937”) to supplement its previouslyissued “Frequently Asked Questions” document under the...
15
Feb
15
Feb
15
Feb
13
Feb
13
Feb
Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for...
13
Feb
12
Feb
ELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 The acute migraine drug market size...